Are You a Slow Caffeine Metabolizer? What the Genetics Really Say

Written by the Nuvirox Research Team

Short answer: the gene is real, the marketing around it is not. If caffeine keeps you up until 2 a.m. or makes your hands shake, there is a good chance you have encountered the claim that you are a genetically slow caffeine metabolizer, and that a DNA test can confirm it. CYP1A2 does clear caffeine, and the rs762551 variant does affect how readily that enzyme ramps up. But the founding study found no measurable genotype effect in people who did not smoke, and a systematic review later noted that over half the studies testing this variant found no difference between genotypes at all. The more honest explanation for why caffeine hits you hard is usually not in your genome.

What does CYP1A2 actually do?

Roughly 95% of ingested caffeine is metabolised in the liver by cytochrome P450 1A2. It converts caffeine into three main metabolites, the most important being paraxanthine, which is nearly as effective as caffeine at blocking adenosine receptors — the mechanism behind caffeine's alerting effect and the subject of our piece on why coffee stops working.

The variant everyone talks about, rs762551, is a single nucleotide change in the first intron of the gene. The A allele is associated with higher enzyme inducibility, and that word is doing the heavy lifting. It does not mean the enzyme is intrinsically faster. It means the enzyme responds more strongly when something induces it — cigarette smoke, cruciferous vegetables, charred meat, or heavy caffeine intake itself. The C allele responds less.

Genotype distribution in the original cohort. Depending on how you define it, roughly half the population carries at least one C allele — which is why the label 'slow metabolizer' applies to so many people.

What the founding study actually found

This is the finding most consumer genetics pages omit. Sachse and colleagues identified the polymorphism and tested its functional significance in 185 healthy non-smokers and 51 smokers, phenotyping each with a 100 mg oral caffeine dose and measuring urinary metabolite ratios. Of the total sample, 46% were homozygous for the A variant, 44% heterozygous, and 10% homozygous for C.

In the 185 non-smokers, there were no significant differences in mean caffeine metabolic ratios between the three genotype groups. In the 51 smokers, the polymorphism had a significant effect (p = 0.008). The variant mattered when the enzyme was being induced and did not measurably matter when it was not. That is a substantially narrower claim than 'this gene determines your caffeine half-life.'

The split result in Sachse et al. (1999). The genotype effect was conditional on enzyme induction, not present at baseline.

What human studies actually show

The cardiovascular association is the strongest evidence that genotype does something clinically. Cornelis and colleagues compared 2,014 people with a first acute nonfatal myocardial infarction against 2,014 matched population controls in Costa Rica between 1994 and 2004. Coffee intake was associated with increased MI risk in carriers of the slow-metabolising variant but not in people homozygous for the rapid allele. That is a large, well-designed case-control study, and it suggests the genotype interacts with heavy coffee consumption in a way that matters.

The exercise performance literature is genuinely inconsistent. Guest and colleagues gave 101 competitive male athletes 0, 2, or 4 mg/kg of caffeine before a 10-km cycling time trial in a split-plot randomised, double-blind, placebo-controlled design. Overall, 4 mg/kg reduced cycling time by 3% versus placebo, and there was a significant genotype interaction. But a 2012 trial by Womack and colleagues, and several since, found different patterns.

A systematic review found the literature was split roughly down the middle. Reviewing studies of the −163C>A polymorphism and caffeine's ergogenic effects, researchers concluded that fast metabolisers appear most likely to benefit — while noting that over half of studies showed no differences in caffeine response between genotypes. When more than half of the tests of a hypothesis fail, the appropriate confidence level is low.

Genotype frequency also varies enormously by population. A study of 576 non-smoking Emirati subjects found 1.4% slow, 16.3% intermediate, and 82.3% rapid metabolisers — a completely different distribution from the European cohorts most consumer tests are calibrated against. Any percentile ranking a DNA report gives you is relative to a reference population that may not be yours.

So why does caffeine actually affect you so much?

Several explanations fit the evidence better than genotype alone, and they are not mutually exclusive. The first is a different gene entirely: ADORA2A encodes the adenosine A2A receptor that caffeine blocks, and variation there is associated with caffeine-induced anxiety and sleep disruption independent of how fast you clear the drug. You can metabolise caffeine at a perfectly ordinary rate and still be unusually sensitive to what it does while it is present.

The second is dose and timing. Caffeine's half-life in a healthy non-smoking adult is roughly five to six hours, which means a 3 p.m. coffee still has a quarter of its caffeine on board at bedtime. The third is habituation: regular consumers develop tolerance to the subjective effects while the sleep disruption persists, so people often underestimate what afternoon caffeine is doing to them. The fourth is sleep debt — caffeine feels far more powerful when you are running a deficit, and far more likely to produce jitteriness.

And several non-genetic factors change CYP1A2 activity substantially. Smoking induces it strongly. Pregnancy slows caffeine clearance dramatically, with half-life extending several-fold in the third trimester. Oral contraceptives inhibit CYP1A2. Cruciferous vegetables induce it. Any of these will swamp a genotype effect.

What a DNA caffeine report can and can't tell you

It can tell you your rs762551 genotype accurately — that part is simple genotyping and consumer arrays do it reliably. What it cannot do is predict your caffeine half-life, your optimal dose, or whether you will sleep badly after an afternoon espresso, because those outcomes depend on receptor genetics, induction status, tolerance, medication, and sleep pressure. There is also no formally recognised ultrarapid CYP1A2 phenotype the way there is for CYP2D6, so any report using that word is applying it loosely.

The same caution applies to a lot of consumer nutrigenomics; we made a similar argument about whether an MTHFR variant explains fatigue. A single common variant rarely determines a complex trait.

Frequently asked questions

How do I find out if I'm actually a slow metabolizer?

The only direct method is phenotyping — measuring caffeine and its metabolites in urine or plasma after a standard dose — which is a research procedure rather than a consumer test. Practically, a simple self-experiment is more informative: hold your last caffeine to before noon for two weeks and see whether sleep onset changes. That measures the outcome you care about rather than a proxy for it.

Does the C allele mean I should avoid coffee?

Not on its own. The Costa Rica data suggest the interaction shows up at higher intakes in slow metabolisers, which argues for moderation rather than avoidance. The European Food Safety Authority's general guidance of up to 400 mg per day for healthy adults remains the reference point, and the more actionable change for most slow metabolisers is timing rather than total amount.

Why do I get jittery from coffee but fine on tea?

Dose is the most likely explanation — a brewed coffee typically has two to three times the caffeine of black tea. Tea also contains L-theanine, which some small studies suggest blunts caffeine's jitteriness, though the evidence is modest. Absorption rate matters too: caffeine consumed with food enters the bloodstream more gradually.

Does pregnancy change caffeine metabolism?

Substantially. CYP1A2 activity falls markedly during pregnancy and caffeine half-life lengthens considerably, particularly in the third trimester. This is one of the clearest non-genetic modifiers of caffeine clearance and a reason pregnancy-specific caffeine guidance exists.

If caffeine stops working, is that a metabolism problem?

Usually not. Tolerance at the adenosine receptor is the more common explanation, and accumulated sleep debt is the more common underlying cause. Caffeine masks sleep pressure rather than removing it, which is why the afternoon slump often returns harder — something we cover in more detail in our piece on the afternoon energy crash.

From Nuvirox

Why we formulated NAD+ Restore

If caffeine has become a tool for masking tiredness rather than sharpening an already-rested brain, the underlying question is about cellular energy production. NAD+ is the coenzyme that makes ATP generation possible, and it declines with age. NAD+ Restore is built around 500 mg of nicotinamide riboside, within the dose range used in published human trials.

• 500 mg Nicotinamide Riboside Chloride (NR) — one of the two most-researched NAD+ precursors, within the dose range used in published human trials.
• 150 mg trans-resveratrol (Japanese Knotweed) and 50 mg quercetin (Sophora japonica) — polyphenols studied alongside NAD+ pathways for cellular health support.
• 10 mg galactomannans from fenugreek — to support absorption.
• 60-day money-back guarantee — long enough to actually evaluate it the way the research says you should.

Learn more about NAD+ Restore →

The bottom line

CYP1A2 genuinely clears your caffeine, and rs762551 genuinely affects how inducible that enzyme is. What the evidence does not support is the confident consumer-genetics story built on top of it. The founding study found no genotype effect in non-smokers. A systematic review found over half of performance studies showed no genotype difference. Genotype frequencies vary dramatically by ancestry. The best-supported clinical finding is that heavy coffee intake interacts with the slow-metabolising variant to raise cardiovascular risk, which argues for moderation. If caffeine wrecks your sleep or makes you anxious, receptor sensitivity, dose, timing, and sleep debt are more likely explanations — and all four are things you can actually change. For a different angle on caffeine and physical fatigue, our piece on beta-alanine and the narrow window where it works covers similar ground about ergogenic aids.

References

1. Sachse C, Brockmöller J, Bauer S, Roots I. Functional significance of a C→A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol. 1999;47(4):445–449. PMID: 10233211. DOI: 10.1046/j.1365-2125.1999.00898.x.
2. Cornelis MC, El-Sohemy A, Kabagambe EK, Campos H. Coffee, CYP1A2 genotype, and risk of myocardial infarction. JAMA. 2006;295(10):1135–1141. PMID: 16522833. DOI: 10.1001/jama.295.10.1135.
3. Guest N, Corey P, Vescovi J, El-Sohemy A. Caffeine, CYP1A2 genotype, and endurance performance in athletes. Med Sci Sports Exerc. 2018;50(8):1570–1578. DOI: 10.1249/MSS.0000000000001596.
4. Womack CJ, Saunders MJ, Bechtel MK, et al. The influence of a CYP1A2 polymorphism on the ergogenic effects of caffeine. J Int Soc Sports Nutr. 2012;9(1):7. DOI: 10.1186/1550-2783-9-7. PMCID: PMC3334681.
5. Grgic J, Pickering C, Bishop DJ, et al. CYP1A2 genotype and acute ergogenic effects of caffeine intake on exercise performance: a systematic review. Eur J Nutr. 2021. DOI: 10.1007/s00394-020-02427-6.
6. Nehlig A. Interindividual differences in caffeine metabolism and factors driving caffeine consumption. Pharmacol Rev. 2018;70(2):384–411.
7. Genetic polymorphisms of cytochrome P450-1A2 (CYP1A2) among Emiratis. PMCID: PMC5608188.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for informational purposes only and is not a substitute for professional medical advice.